188 related articles for article (PubMed ID: 26724663)
1. Dynamic contrast-enhanced perfusion area detector CT for non-small cell lung cancer patients: Influence of mathematical models on early prediction capabilities for treatment response and recurrence after chemoradiotherapy.
Ohno Y; Koyama H; Fujisawa Y; Yoshikawa T; Seki S; Sugihara N; Sugimura K
Eur J Radiol; 2016 Jan; 85(1):176-186. PubMed ID: 26724663
[TBL] [Abstract][Full Text] [Related]
2. Dynamic contrast-enhanced perfusion area-detector CT assessed with various mathematical models: Its capability for therapeutic outcome prediction for non-small cell lung cancer patients with chemoradiotherapy as compared with that of FDG-PET/CT.
Ohno Y; Fujisawa Y; Koyama H; Kishida Y; Seki S; Sugihara N; Yoshikawa T
Eur J Radiol; 2017 Jan; 86():83-91. PubMed ID: 28027771
[TBL] [Abstract][Full Text] [Related]
3. Dynamic Contrast-enhanced Area-detector CT vs Dynamic Contrast-enhanced Perfusion MRI vs FDG-PET/CT: Comparison of Utility for Quantitative Therapeutic Outcome Prediction for NSCLC Patients Undergoing Chemoradiotherapy.
Seki S; Fujisawa Y; Yui M; Kishida Y; Koyama H; Ohyu S; Sugihara N; Yoshikawa T; Ohno Y
Magn Reson Med Sci; 2020 Feb; 19(1):29-39. PubMed ID: 30880291
[TBL] [Abstract][Full Text] [Related]
4. Dynamic Contrast-Enhanced Perfusion Area-Detector CT: Preliminary Comparison of Diagnostic Performance for N Stage Assessment With FDG PET/CT in Non-Small Cell Lung Cancer.
Ohno Y; Fujisawa Y; Sugihara N; Kishida Y; Seki S; Koyama H; Yoshikawa T
AJR Am J Roentgenol; 2017 Nov; 209(5):W253-W262. PubMed ID: 28929810
[TBL] [Abstract][Full Text] [Related]
5. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
[TBL] [Abstract][Full Text] [Related]
6. (99m)Tc-3PRGD 2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab.
Ma Q; Min K; Wang T; Chen B; Wen Q; Wang F; Ji T; Gao S
Ann Nucl Med; 2015 Jul; 29(6):519-27. PubMed ID: 25911312
[TBL] [Abstract][Full Text] [Related]
7. Solitary pulmonary nodule: Comparison of quantitative capability for differentiation and management among dynamic CE-perfusion MRI at 3 T system, dynamic CE-perfusion ADCT and FDG-PET/CT.
Ohno Y; Fujisawa Y; Yui M; Takenaka D; Koyama H; Sugihara N; Yoshikawa T
Eur J Radiol; 2019 Jun; 115():22-30. PubMed ID: 31084755
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of computed tomography texture features in non-small cell lung cancers treated with definitive concomitant chemoradiotherapy.
Ahn SY; Park CM; Park SJ; Kim HJ; Song C; Lee SM; McAdams HP; Goo JM
Invest Radiol; 2015 Oct; 50(10):719-25. PubMed ID: 26020832
[TBL] [Abstract][Full Text] [Related]
9. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
[TBL] [Abstract][Full Text] [Related]
10. Tumour response in non-small-cell lung cancer patients treated with chemoradiotherapy - Can spectral CT predict recurrence?
Fehrenbach U; Feldhaus F; Kahn J; Böning G; Maurer MH; Renz D; Frost N; Streitparth F
J Med Imaging Radiat Oncol; 2019 Oct; 63(5):641-649. PubMed ID: 31282130
[TBL] [Abstract][Full Text] [Related]
11. Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography.
Huang YS; Chen JL; Chen JY; Lee YF; Huang JY; Kuo SH; Yen RF; Chang YC
Strahlenther Onkol; 2019 Aug; 195(8):707-718. PubMed ID: 30610356
[TBL] [Abstract][Full Text] [Related]
12. Hybrid Type iterative reconstruction method vs. filter back projection method: Capability for radiation dose reduction and perfusion assessment on dynamic first-pass contrast-enhanced perfusion chest area-detector CT.
Ohno Y; Koyama H; Fujisawa Y; Yoshikawa T; Inokawa H; Sugihara N; Seki S; Sugimura K
Eur J Radiol; 2016 Jan; 85(1):164-175. PubMed ID: 26724662
[TBL] [Abstract][Full Text] [Related]
13. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
14. Chemical Exchange Saturation Transfer MRI: Capability for Predicting Therapeutic Effect of Chemoradiotherapy on Non-Small Cell Lung Cancer Patients.
Ohno Y; Yui M; Yamamoto K; Takenaka D; Koyama H; Nagata H; Ueda T; Ikeda H; Ozawa Y; Toyama H; Yoshikawa T
J Magn Reson Imaging; 2023 Jul; 58(1):174-186. PubMed ID: 36971493
[TBL] [Abstract][Full Text] [Related]
15. Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy.
Tacelli N; Santangelo T; Scherpereel A; Duhamel A; Deken V; Klotz E; Cortot A; Lafitte JJ; Wallyn F; Remy J; Remy-Jardin M
Eur Radiol; 2013 Aug; 23(8):2127-36. PubMed ID: 23553586
[TBL] [Abstract][Full Text] [Related]
16. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy.
Hwang SH; Yoo MR; Park CH; Jeon TJ; Kim SJ; Kim TH
Eur Radiol; 2013 Jun; 23(6):1573-81. PubMed ID: 23300040
[TBL] [Abstract][Full Text] [Related]
18. Comparison of quantitatively analyzed dynamic area-detector CT using various mathematic methods with FDG PET/CT in management of solitary pulmonary nodules.
Ohno Y; Nishio M; Koyama H; Fujisawa Y; Yoshikawa T; Matsumoto S; Sugimura K
AJR Am J Roentgenol; 2013 Jun; 200(6):W593-602. PubMed ID: 23701089
[TBL] [Abstract][Full Text] [Related]
19. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
[TBL] [Abstract][Full Text] [Related]
20. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]